News
LUNG
1.480
+6.47%
0.090
Weekly Report: what happened at LUNG last week (0629-0703)?
Weekly Report · 1d ago
Weekly Report: what happened at LUNG last week (0622-0626)?
Weekly Report · 06/29 10:22
Weekly Report: what happened at LUNG last week (0615-0619)?
Weekly Report · 06/22 10:32
Weekly Report: what happened at LUNG last week (0608-0612)?
Weekly Report · 06/15 10:33
Weekly Report: what happened at LUNG last week (0601-0605)?
Weekly Report · 06/08 10:28
Don't Ignore The Insider Selling In Pulmonx
Simply Wall St · 06/07 13:10
Pulmonx Shareholders Back Board, Auditor and Pay Program
TipRanks · 06/04 21:20
Pulmonx shareholders elect Class III directors at annual meeting
PUBT · 06/04 20:05
Pulmonx Executives Quietly Unload a Wave of Shares in Coordinated Insider Moves
TipRanks · 06/04 02:08
Pulmonx grants 84,300 RSUs to 17 new hires under inducement plan
PUBT · 06/01 20:08
PULMONX CORPORATION ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/01 20:05
Weekly Report: what happened at LUNG last week (0525-0529)?
Weekly Report · 06/01 10:34
Weekly Report: what happened at LUNG last week (0518-0522)?
Weekly Report · 05/25 10:37
Weekly Report: what happened at LUNG last week (0511-0515)?
Weekly Report · 05/18 10:37
Weekly Report: what happened at LUNG last week (0504-0508)?
Weekly Report · 05/11 10:34
Pulmonx publishes investor presentation on Zephyr valves for severe emphysema treatment
PUBT · 05/05 05:52
Weekly Report: what happened at LUNG last week (0427-0501)?
Weekly Report · 05/04 10:30
Pulmonx Earnings Call: Margin Gains Amid Growth Pause
TipRanks · 05/01 00:58
Lake Street Remains a Buy on Pulmonx (LUNG)
TipRanks · 04/30 16:36
Pulmonx (LUNG) Q1 2026 Earnings Transcript
The Motley Fool · 04/30 16:25
More
Webull provides a variety of real-time LUNG stock news. You can receive the latest news about Pulmonx Corp through multiple platforms. This information may help you make smarter investment decisions.
About LUNG
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.